Redefining BASDAI cut-offs in axial spondyloarthritis: implications for patients' eligibility for treatment with biologic disease-modifying antirheumatic drugs

Objective To compare a newly proposed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off for high disease activity (BASDAI≥2.5) with the corresponding Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off (ASDAS≥2.1) as an eligibility criterion for initiating a biologic disease-modifying antirheumatic drug (bDMARD) in routine care patients with axial spondyloarthritis (axSpA). Methods Real-world patients with axSpA initiating their first bDMARD from 9 European registries were analysed. Patients were categorised into 4 subgroups according to the fulfilment of ASDAS and BASDAI criteria at baseline, and treatment effect was assessed at 6 months using several response and remission outcomes. Adjusted logistic regression analyses were performed to determine whether fulfilling ASDAS and BASDAI criteria was associated with achieving the treatment outcomes. Results Of 6,329 patients included, 90.9% fulfilled both ASDAS and BASDAI eligibility criteria at baseline, 2.5% and 2.7% fulfilled either ASDAS or BASDAI criterion alone, while 3.8% fulfilled neither. The subgroup fulfilling both criteria demonstrated the highest responses at 6 months, while the highest remission outcomes were observed in the subgroup fulfilling neither criterion. Fulfilling either criterion at baseline was significantly associated with achieving response outcomes at 6 months, whereas a negative association was observed for remission outcomes. Conclusion In a multinational European cohort, a very large overlap between the BASDAI and the ASDAS eligibility criteria was shown, and the predictive ability of the two criteria to achieve treatment outcomes was comparable. These findings support the use of BASDAI≥2.5 as a criterion for initiating bDMARD therapy in axSpA, particularly when ASDAS is unavailable.

Authors

Institutions

Publication Details

Journal
The Journal of Rheumatology
Published
2026-11-15
DOI
https://doi.org/10.3899/jrheum.2026-0445
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Redefining BASDAI cut-offs in axial spondyloarthritis: implications for patients' eligibility for treatment with biologic disease-modifying antirheumatic drugs

Stylianos Georgiadis, Adrian Ciurea, Andreas Reich, Brigitte Michelsen et al.
The Journal of Rheumatology
Spondyloarthritis Studies and Treatments
article

Redefining BASDAI cut-offs in axial spondyloarthritis: implications for patients' eligibility for treatment with biologic disease-modifying antirheumatic drugs

Stylianos Georgiadis, Adrian Ciurea, Andreas Reich, Brigitte Michelsen, Daniela Di Giuseppe, Anne Gitte Loft, Michael John Nissen, Laura Kuusalo, Lykke Midtbøll Ørnbjerg, Gary John Macfarlane, Ólafur Pálsson, Gareth Tudor Jones, Tore K Kvien, Björn Guðbjörnsson, Merete Lund Hetland, Herman F. Mann, Anne C. Regierer, Mikkel Østergaard, Kristýna Bubová, Bente Glintborg, Sella Aarrestad Provan, Corina Mogoşan, Gunnstein Bakland, Žiga Rotar, Karel Pavelká, Jarno Rutanen, Cătălin Codreanu, Mehrdad Shoae Kazemi, Helena Santos, Katja Perdan Pirkmajer
article en

Abstract

Objective To compare a newly proposed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off for high disease activity (BASDAI≥2.5) with the corresponding Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off (ASDAS≥2.1) as an eligibility criterion for initiating a biologic disease-modifying antirheumatic drug (bDMARD) in routine care patients with axial spondyloarthritis (axSpA). Methods Real-world patients with axSpA initiating their first bDMARD from 9 European registries were analysed. Patients were categorised into 4 subgroups according to the fulfilment of ASDAS and BASDAI criteria at baseline, and treatment effect was assessed at 6 months using several response and remission outcomes. Adjusted logistic regression analyses were performed to determine whether fulfilling ASDAS and BASDAI criteria was associated with achieving the treatment outcomes. Results Of 6,329 patients included, 90.9% fulfilled both ASDAS and BASDAI eligibility criteria at baseline, 2.5% and 2.7% fulfilled either ASDAS or BASDAI criterion alone, while 3.8% fulfilled neither. The subgroup fulfilling both criteria demonstrated the highest responses at 6 months, while the highest remission outcomes were observed in the subgroup fulfilling neither criterion. Fulfilling either criterion at baseline was significantly associated with achieving response outcomes at 6 months, whereas a negative association was observed for remission outcomes. Conclusion In a multinational European cohort, a very large overlap between the BASDAI and the ASDAS eligibility criteria was shown, and the predictive ability of the two criteria to achieve treatment outcomes was comparable. These findings support the use of BASDAI≥2.5 as a criterion for initiating bDMARD therapy in axSpA, particularly when ASDAS is unavailable.

The Journal of Rheumatology
University of Copenhagen (DK), University Hospital of North Norway (NO), University of Ljubljana (SI), University of Turku (FI), Carol Davila University of Medicine and Pharmacy (RO), University of Iceland (IS), University of Oslo (NO), Lund University (SE), University of Aberdeen (GB), University of Zurich (CH), Aarhus University (DK), Charles University (CZ), Ljubljana University Medical Centre (SI), Turku University Hospital (FI), Glostrup Hospital (DK), Aarhus University Hospital (DK), Rigshospitalet (DK), Karolinska Institutet (SE), Institute of Rheumatology (CZ), German Rheumatism Research Centre (DE), University Hospital of Zurich (CH), University Hospital of Geneva (CH), National University Hospital of Iceland (IS), University of Inland Norway (NO), Diakonhjemmet Hospital (NO), Tampere University Hospital (FI), Skåne University Hospital (SE), Sørlandet Sykehus (NO), Instituto Português de Reumatologia (PT), Comprehensive Health Research Centre (PT), UiT The Arctic University of Norway (NO)
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon